$6.20
+0.18(3.08%)
Mkt Cap $35M
$3.33
$11.66
52-Week Range
At a Glance
AI-generated8-K
On March 27, 2026, Cingulate Inc. appointed Zhanpeng 'Frederick' Jiang as an independent Class I Director and member of all three Board committees following stockholder approval.$35M
Market Cap
—
Revenue
-$23M
Net Income
Employees13
Fundamentals
How The Business Makes Money
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001862150
ISINUS17248W3034
CUSIP17248W105
Phone913 942 2300
Address1901 West 47th Place, Kansas City, KS, 66205, US
SEC EDGAR